1.87  0.11 (6.25%)		06-18 16:00
Open: 1.835 High: 1.93 Volume: 3,859,940		Pre. Close: 1.76 Low: 1.79 Market Cap: 325(M)

Short term
Mid term
Targets	6-month :	2.29	1-year :	2.52
Resists	First :	1.96	Second :	2.16
Pivot price	1.82
Supports	First :	1.63	Second :	1.36
MAs	MA(5) :	1.76	MA(20) :	1.87
	MA(100) :	1.88	MA(250) :	1.58
MACD	MACD :	-0.1	Signal :	-0.1
%K %D	K(14,3) :	32.1	D(3) :	22.9
RSI	RSI(14): 50.6
52-week	High :	2.85	Low :	0.52

Price has closed above its short-term moving average. Short-term moving average is currently below mid-term; and below long-term moving average. From the relationship between price and moving averages: This stock is NEUTRAL in short-term; and NEUTRAL in mid-long term.
[ PALI ] has closed below upper band by 41.4%. Bollinger Bands are 2.6% wider than normal. The current width of the bands does not suggest anything about the future direction or movement of prices.

If tomorrow:	Open lower	Open higher
High:	1.93 - 1.95	1.95 - 1.96
Low:	1.77 - 1.78	1.78 - 1.79
Close:	1.85 - 1.87	1.87 - 1.89

Palisade Bio, Inc. is a clinical-stage biopharmaceutical firm dedicated to identifying, advancing, and bringing to market orally administered treatments for significant conditions stemming from a compromised gastrointestinal mucosal barrier. The company's primary therapeutic candidate, LB1148, is an oral liquid formulation designed to inhibit digestive enzymes. Its goal is to safeguard gut integrity when the intestine experiences stress due to factors such as diminished blood supply, infections, or surgical procedures. Established in 2005, the company maintains its headquarters in Carlsbad, California.

Thu, 18 Jun 2026
Director at Palisade Bio (PALI) granted 336,904 RSUs with three-year vesting - Stock Titan

Thu, 18 Jun 2026
Palisade Bio (PALI) director Robert Baltera Jr. files initial Form 3 - Stock Titan

Thu, 18 Jun 2026
Palisade Bio Inc (PALI) Technical Analysis: Support, Resistance, Indicators & Moving Averages - TradingKey

Wed, 17 Jun 2026
Palisade Bio Inc (PALI) Dividends & Stock Splits: Historical Payouts and Event Timeline - TradingKey

Fri, 12 Jun 2026
Palisade Bio (PALI) director Jordan Michael Zwick files baseline Form 3 - Stock Titan

Fri, 12 Jun 2026
Palisade Bio (PALI) Holds Steady Near Key Support After Modest Gain - Triple Top - lwvtexas.org

Price to Book Value: P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly.	Underperform
Price to Earnings: PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS).	Underperform
Discounted cash flow: DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows.	Outperform
Return on Assets: ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit.	Underperform
Return on Equity: ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency.	Underperform
Debt to Equity: evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn.	Underperform

Exchange: NASDAQ
Sector: Healthcare
Industry: Biotechnology
Shares Out	174 (M)
Shares Float	128 (M)
Held by Insiders	0 (%)
Held by Institutions	93.7 (%)
Shares Short	30,810 (K)
Shares Short P.Month	26,150 (K)

EPS	0.11
EPS Est Next Qtrly	0
EPS Est This Year	0
EPS Est Next Year	0
Book Value (p.s.)	0.75
Profit Margin	0 %
Operating Margin	0 %
Return on Assets (ttm)	-23.4 %
Return on Equity (ttm)	-36.5 %
Qtrly Rev. Growth	0 %
Gross Profit (p.s.)	0
Sales Per Share	0
EBITDA (p.s.)	-0.16
Qtrly Earnings Growth	0 %
Operating Cash Flow	-12 (M)
Levered Free Cash Flow	-10 (M)

PE Ratio	15.58
PEG Ratio	0
Price to Book value	2.46
Price to Sales	0
Price to Cash Flow	-26.18

Dividend	0
Forward Dividend	0
Dividend Yield	0%
Dividend Pay Date	Invalid DateTime.
Ex-Dividend Date	Invalid DateTime.